Lyka Labs has obtained CDSCO approval to manufacture and market Pregabalin Gel 8% w/w in India. This novel topical treatment, aimed at alleviating Diabetic Neuropathic Pain (DNP), marks a crucial step forward in the management of diabetes-related neuropathy in India, where the prevalence of diabetes has risen dramatically.
Clinical trials showed that it is effective and well-tolerated, with fewer side effects than oral Pregabalin. This might be a great step for Lyka Labs.
Lyka is a pharmaceutical firm with a specialization in sterile and topical preparations. Lyka’s R&D Centre in Mumbai is actively developing a wide range of new formulations and drug delivery systems in its focus areas of Lyophilized Injectables and Topical Preparations.
TOPICS:
lyka labs